Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MaaT Pharma
Biotech
MaaT's phase 3 GvHD trial hits goal, teeing up microbiome filing
The phase 3 graft-versus-host disease trial hit its primary endpoint, positioning MaaT to seek approval of the microbiome therapy in mid-2025.
Nick Paul Taylor
Jan 9, 2025 5:18am
MBX Biosciences, MaaT Pharma and more—Chutes & Ladders
Jun 28, 2024 8:30am
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
Apr 15, 2024 7:05am
FDA drops resistance to fecal pooling, clears MaaT for phase 3
Apr 24, 2023 6:10am
After 18-month hold, MaaT sees end to impasse with FDA
Feb 3, 2023 9:55am
FDA declines to free MaaT's microbiome drug from a clinical hold
Aug 10, 2022 1:47pm
